Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Vir Biotechnology Inc’s stock clocked out at $5.22, down -0.57% from its previous closing price of $5.25. In other words, the price has decreased by -$0.57 from its previous closing price. On the day, 0.79 million shares were traded.
Ratios:
To gain a deeper understanding of VIR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.79 and its Current Ratio is at 6.79. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $23 previously.
On September 08, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $23 to $14.
JP Morgan Upgraded its Neutral to Overweight on March 06, 2023, whereas the target price for the stock was revised from $35 to $34.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 11 ’25 when GEORGE SCANGOS bought 19,957 shares for $5.41 per share.
GEORGE SCANGOS bought 50,000 shares of VIR for $273,885 on Jun 10 ’25. On Jun 09 ’25, another insider, GEORGE SCANGOS, who serves as the Former Director of the company, bought 50,000 shares for $5.41 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 34.59 while its Price-to-Book (P/B) ratio in mrq is 0.69.
Stock Price History:
Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.32. The 50-Day Moving Average of the stock is -3.04%, while the 200-Day Moving Average is calculated to be -30.85%.
Shares Statistics:
A total of 138.06M shares are outstanding, with a floating share count of 89.08M. Insiders hold about 35.56% of the company’s shares, while institutions hold 53.56% stake in the company.
Earnings Estimates
The stock of Vir Biotechnology Inc (VIR) is currently being evaluated by 7.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.54 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$2.48 and -$4.07 for the fiscal current year, implying an average EPS of -$3.19. EPS for the following year is -$3.08, with 8.0 analysts recommending between -$2.23 and -$4.23.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $68M, while the lowest revenue estimate was $3M, resulting in an average revenue estimate of $16.91M. In the same quarter a year ago, actual revenue was $74.2MBased on 8 analysts’ estimates, the company’s revenue will be $16.48M in the next fiscal year. The high estimate is $53M and the low estimate is $3M.
